Hepcidin in chronic kidney disease: Not an anaemia management tool, but promising as a cardiovascular biomarker

Netherlands Journal of Medicine

Volumn 73, Issue 3, 2015, Pages 108-118

  van der Weerd, N C ^a   Grooteman, M P C ^b   Nube M J ^b   ter Wee, P M ^b   Swinkels, D W ^c   Gaillard, C A J M ^d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Anaemia; Cardiovascular; Chronic kidney disease; Dialysis; Hepcidin; Iron

Indexed keywords

ALBUMIN; ANTIANEMIC AGENT; BONE MORPHOGENETIC PROTEIN; C REACTIVE PROTEIN; CHOLESTEROL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HEMOJUVELIN; HEPCIDIN; HEPCIDIN 25; INTERLEUKIN 6; IRON; JANUS KINASE 2; MATRIPTASE; SMAD PROTEIN; STAT3 PROTEIN; TRANSFERRIN; TRANSFERRIN RECEPTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ANEMIA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL DECISION MAKING; END STAGE RENAL DISEASE; HORMONE ACTION; HORMONE STRUCTURE; HUMAN; IMMUNOCHEMISTRY; INFLAMMATION; IRON DEFICIENCY; IRON THERAPY; MASS SPECTROMETRY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN FUNCTION; RADIOIMMUNOASSAY; REGULATORY MECHANISM; RENAL REPLACEMENT THERAPY; REVIEW; CHRONIC KIDNEY FAILURE; DISEASE MANAGEMENT; METABOLISM;

ANEMIA; BIOMARKERS; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; HEPCIDINS; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84926627597     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 2001;276:7806-10.
2. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276:7811-9.
3. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A. 2001;98:8780-5.
4. Fleming RE, Sly WS. Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci U S A. 2001;98:8160-2.
5. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-23.
6. Babitt JL, Lin HY. Mechanisms of Anemia in CKD. J Am Soc Nephrol. 2012;23:1631-4.
7. Eleftheriadis T, Liakopoulos V, Antoniadi G, Kartsios C, Stefanidis I. The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Semin Dial. 2009;22:70-7.
8. Swinkels DW, Wetzels JF. Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease? Nephrol Dial Transplant. 2008;23:2450-3.
9. Zaritsky J, Young B, Wang HJ, et al. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1051-6.
10. Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clin Chem. 2011;57:1650-69.
11. Clark RJ, Tan CC, Preza GC, Nemeth E, Ganz T, Craik DJ. Understanding the structure/activity relationships of the iron regulatory peptide hepcidin. Chemistry & biology. 2011;18:336-43.
12. Jordan JB, Poppe L, Haniu M, et al. Hepcidin revisited, disulfide connectivity, dynamics, and structure. J Biol Chem. 2009;284:24155-67.
13. Laarakkers CM, Wiegerinck ET, Klaver S, et al. Improved mass spectrometry assay for plasma hepcidin: detection and characterization of a novel hepcidin isoform. PLoS One. 2013;8:e75518.
14. Kemna EH, Tjalsma H, Podust VN, Swinkels DW. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem. 2007;53:620-8.
15. Kroot JJ, Laarakkers CM, Geurts-Moespot AJ, et al. Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem. 2010;56:1570-9.
16. Campostrini N, Castagna A, Zaninotto F, et al. Evaluation of hepcidin isoforms in hemodialysis patients by a proteomic approach based on SELDI-TOF MS. J Biomed Biotechnol. 2010;2010:329646.
17. Peters HPE, Laarakkers CMM, Swinkels DW, Wetzels JFM. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol Dial Transplant. 2010;25:848-53.
18. Tomosugi N, Kawabata H, Wakatabe R, et al. Detection of serum hepcidin in renal failure and inflammation by using ProteinChip System. Blood. 2006;108:1381-7.
19. Itkonen O, Stenman UH, Parkkinen J, Soliymani R, Baumann M, Hamalainen E. Binding of hepcidin to plasma proteins. Clin Chem. 2012;58:1158-60.
20. Peslova G, Petrak J, Kuzelova K, et al. Hepcidin, the hormone of iron metabolism, is bound specifically to alpha-2-macroglobulin in blood. Blood. 2009;113:6225-36.
21. Huang ML, Austin CJ, Sari MA, et al. Hepcidin Bound to alpha2-Macroglobulin Reduces Ferroportin-1 Expression and Enhances Its Activity at Reducing Serum Iron Levels. J Biol Chem. 2013;288:25450-65.
22. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112:4292-7.
23. Swinkels DW, Girelli D, Laarakkers C, et al. Advances in quantitative hepcidin measurements by time-of-flight mass spectrometry. PLoS One. 2008;3(7):e2706.
24. Peters HP, Laarakkers CM, Pickkers P, et al. Tubular reabsorption and local production of urine hepcidin-25. BMC Nephrol. 2013;14:70.
25. Pelusi S, Girelli D, Rametta R, et al. The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis. BMC Nephrol. 2013;14:48.
26. Valenti L, Girelli D, Valenti GF, et al. HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients. Clin J Am Soc Nephrol. 2009;4:1331-7.
27. Galesloot TE, Geurts-Moespot AJ, den Heijer M, et al. Associations of common variants in HFE and TMPRSS6 with iron parameters are independent of serum hepcidin in a general population: a replication study. J Med Genet. 2013;50:593-8.
28. Ganz T, Nemeth E. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program. 2011;2011:538-42.
29. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271-6.
30. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090-3.
31. Farnaud S, Rapisarda C, Bui T, Drake A, Cammack R, Evans RW. Identification of an iron-hepcidin complex. Biochem J. 2008;413:553-7.
32. Meynard D, Babitt JL, Lin HY. The liver: conductor of systemic iron balance. Blood. 2014;123:168-76.
33. Fleming RE, Ponka P. Iron overload in human disease. N Engl J Med. 2012;366:348-59.
34. Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 2012;87:392-400.
35. Mayeur C, Lohmeyer LK, Leyton P, et al. The type I BMP receptor Alk3 is required for the induction of hepatic hepcidin gene expression by interleukin-6. Blood. 2014;123:2261-8.
36. Kautz L, Nemeth E. Molecular liaisons between erythropoiesis and iron metabolism. Blood. 2014;124:479-82.
37. Zhang AS, Anderson SA, Wang J, et al. Suppression of hepatic hepcidin expression in response to acute iron deprivation is associated with an increase of matriptase-2 protein. Blood. 2011;117:1687-99.
38. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol. 2009;122:78-86.
39. Kemna EH, Tjalsma H, Willems HL, Swinkels DW. Hepcidin: from discovery to differential diagnosis. Haematologica. 2008;93:90-7.
40. Kroot JJ, Hendriks JC, Laarakkers CM, et al. (Pre)analytical imprecision, between-subject variability, and daily variations in serum and urine hepcidin: implications for clinical studies. Anal Biochem. 2009;389:124-9.
41. Schaap CC, Hendriks JC, Kortman GA, et al. Diurnal rhythm rather than dietary iron mediates daily hepcidin variations. Clin Chem. 2013;59(3):527-35.
42. Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int. 2009;75:976-81.
43. Macdougall IC, Malyszko J, Hider RC, Bansal SS. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin J Am Soc Nephrol. 2010;5:1681-9.
44. Kroot JJ, Kemna EH, Bansal SS, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica. 2009;94:1748-52.
45. Kroot JJ, van Herwaarden AE, Tjalsma H, Jansen RT, Hendriks JC, Swinkels DW. Second round robin for plasma hepcidin methods: First steps toward harmonization. Am J Hematol. 2012;87:977-83.
46. Butterfield AM, Luan P, Witcher DR, et al. A dual-monoclonal sandwich ELISA specific for hepcidin-25. Clin Chem. 2010;56:1725-32.
47. Mercadel L, Metzger M, Haymann JP, et al. The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLoS One. 2014;9:e99781.
48. Valenti L, Messa P, Pelusi S, Campostrini N, Girelli D. Hepcidin levels in chronic hemodialysis patients: a critical evaluation. Clinical chemistry and laboratory medicine : CCLM / FESCC. 2014;52:613-9.
49. Uehata T, Tomosugi N, Shoji T, et al. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study. Nephrol Dial Transplant. 2012;27:1076-83.
50. van der Putten K, Jie KE, van den Broek D, et al. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur J Heart Fail. 2010;12:943-50.
51. van der Weerd NC, Grooteman MP, Bots ML, et al. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents. PLoS One. 2012;7:e39783.
52. Kuragano T, Shimonaka Y, Kida A, et al. Determinants of hepcidin in patients on maintenance hemodialysis: role of inflammation. Am J Nephrol. 2010;31:534-40.
53. Malyszko J, Malyszko JS, Kozminski P, Mysliwiec M. Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin. Ren Fail. 2009;31:876-83.
54. Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153:23-33.
55. Weiss G, Theurl I, Eder S, et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest. 2009;39:883-90.
56. Zaritsky J, Young B, Gales B, et al. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients. Clin J Am Soc Nephrol. 2010;5:1010-4.
57. Kato A, Tsuji T, Luo J, Sakao Y, Yasuda H, Hishida A. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients. Am J Nephrol. 2008;28:115-21.
58. Kuragano T, Furuta M, Shimonaka Y, et al. The removal of serum hepcidin by different dialysis membranes. Int J Artif Organs. 2013;36:633-9.
59. Costa E, Swinkels DW, Laarakkers CM, et al. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients. Acta Haematol. 2009;122:226-9.
60. Ford BA, Eby CS, Scott MG, Coyne DW. Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients. Kidney Int. 2010;78:769-73.
61. Tessitore N, Girelli D, Campostrini N, et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant. 2010;25:3996-4002.
62. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1 Suppl 1:S4-S8.
63. Sasu BJ, Cooke KS, Arvedson TL, et al. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood. 2010;115:3616-24.
64. Ashby DR, Gale DP, Busbridge M, et al. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica. 2010;95:505-8.
65. Chand S, Ward DG, Ng ZY, et al. Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease. J Nephrol. 2014. [Epub ahead of print]
66. Stancu S, Barsan L, Stanciu A, Mircescu G. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease? Clin J Am Soc Nephrol. 2010;5:409-16.
67. Peters HP, Rumjon A, Bansal SS, et al. Intra-individual variability of serum hepcidin-25 in haemodialysis patients using mass spectrometry and ELISA. Nephrol Dial Transplant. 2012;27:3923-9.
68. Zaritsky JJ, Young BY. The utility of multivariate analysis in the study of hepcidin. Kidney Int. 2009;76:912; author reply -3.
69. Niihata K, Tomosugi N, Uehata T, et al. Serum hepcidin-25 levels predict the progression of renal anemia in patients with non-dialysis chronic kidney disease. Nephrol Dial Transplant. 2012;27:4378-85.
70. Saeed O, Otsuka F, Polavarapu R, et al. Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:299-307.
71. Li JJ, Meng X, Si HP, et al. Hepcidin destabilizes atherosclerotic plaque via overactivating macrophages after erythrophagocytosis. Arterioscler Thromb Vasc Biol. 2012;32:1158-66.
72. Finn AV, Nakano M, Polavarapu R, et al. Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques. J Am Coll Cardiol. 2012;59:166-77.
73. Valenti L, Swinkels DW, Burdick L, et al. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2011;21:568-75.
74. Valenti L, Dongiovanni P, Motta BM, et al. Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Arterioscler Thromb Vasc Biol. 2011;31:683-90.
75. Abdel-Khalek MA, El-Barbary AM, Essa SA, Ghobashi AS. Serum hepcidin: a direct link between anemia of inflammation and coronary artery atherosclerosis in patients with rheumatoid arthritis. J Rheumatol. 2011;38:2153-9.
76. Galesloot TE, Holewijn S, Kiemeney LA, de Graaf J, Vermeulen SH, Swinkels DW. Serum hepcidin is associated with presence of plaque in postmenopausal women of a general population. Arterioscler Thromb Vasc Biol. 2014;34:446-56.
77. Nakanishi T, Hasuike Y, Otaki Y, Kida A, Nonoguchi H, Kuragano T. Hepcidin: another culprit for complications in patients with chronic kidney disease? Nephrol Dial Transplant. 2011;26:3092-100.
78. Kuragano T, Itoh K, Shimonaka Y, et al. Hepcidin as well as TNF-alpha are significant predictors of arterial stiffness in patients on maintenance hemodialysis. Nephrol Dial Transplant. 2011;26:2663-7.
79. Ulu SM, Yuksel S, Altuntas A, et al. Associations between serum hepcidin level, FGF-21 level and oxidative stress with arterial stiffness in CAPD patients. Int Urol Nephrol. 2014;46:2409-14.
80. Hsieh YP, Huang CH, Lee CY, Chen HL, Lin CY, Chang CC. Hepcidin-25 negatively predicts left ventricular mass index in chronic kidney disease patients. World J Nephrol. 2013;2:38-43.
81. Mostovaya IM, Bots ML, van den Dorpel MA, et al. Left ventricular mass in dialysis patients, determinants and relation with outcome. Results from the COnvective TRansport STudy (CONTRAST). PLoS One. 2014;9:e84587.
82. van der Weerd NC, Grooteman MP, Bots ML, et al. Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients. Nephrol Dial Transplant. 2013;28:3062-71.
83. Theurl I, Theurl M, Seifert M, et al. Autocrine formation of hepcidin induces iron retention in human monocytes. Blood. 2008;111:2392-9.
84. Sullivan JL. Macrophage iron, hepcidin, and atherosclerotic plaque stability. Exp Biol Med. 2007;232:1014-20.
85. Sullivan JL. Iron in arterial plaque: modifiable risk factor for atherosclerosis. Biochim Biophys Acta. 2009;1790:718-23.
86. Kautz L, Gabayan V, Wang X, et al. Testing the iron hypothesis in a mouse model of atherosclerosis. Cell Reports. 2013;5:1436-42.
87. Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol. 2008;3:505-21.
88. Neven E, De Schutter TM, Behets GJ, Gupta A, D’Haese PC. Iron and vascular calcification. Is there a link? Nephrol Dial Transplant. 2011;26:1137-45.
89. Shroff R, Long DA, Shanahan C. Mechanistic Insights into Vascular Calcification in CKD. J Am Soc Nephrol. 2013;24:179-89.
90. Maruyama Y, Yokoyama K, Yamamoto H, Nakayama M, Hosoya T. Do serum hepcidin-25 levels correlate with oxidative stress in patients with chronic kidney disease not receiving dialysis? Clin Nephrol. 2012;78:281-6.
91. Nemeth E. Anti-hepcidin therapy for iron-restricted anemias. Blood. 2013;122:2929-31.
92. van Eijk LT, John AS, Schwoebel F, et al. Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood. 2014;124:2643-6.
93. Samouilidou E, Pantelias K, Petras D, et al. Serum hepcidin levels are associated with serum triglycerides and interleukin-6 concentrations in patients with end-stage renal disease. Ther Apher Dial. 2014;18:279-83.
94. Troutt JS, Butterfield AM, Konrad RJ. Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates. J Clin Lab Anal. 2013;27:504-10.